KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Operating Leases (2019 - 2026)

NovoCure's Operating Leases history spans 8 years, with the latest figure at $39.5 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 2.06% to $39.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $39.5 million, a 2.06% decrease, with the full-year FY2025 number at $41.6 million, up 108.54% from a year prior.
  • Operating Leases hit $39.5 million in Q1 2026 for NovoCure, down from $41.6 million in the prior quarter.
  • Over the last five years, Operating Leases for NVCR hit a ceiling of $42.9 million in Q2 2025 and a floor of $13.4 million in Q2 2022.
  • Historically, Operating Leases has averaged $26.3 million across 5 years, with a median of $21.7 million in 2024.
  • Biggest five-year swings in Operating Leases: decreased 27.17% in 2024 and later soared 108.54% in 2025.
  • Tracing NVCR's Operating Leases over 5 years: stood at $18.8 million in 2022, then soared by 46.15% to $27.4 million in 2023, then decreased by 27.17% to $20.0 million in 2024, then soared by 108.54% to $41.6 million in 2025, then dropped by 5.21% to $39.5 million in 2026.
  • Business Quant data shows Operating Leases for NVCR at $39.5 million in Q1 2026, $41.6 million in Q4 2025, and $42.7 million in Q3 2025.